<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025710</url>
  </required_header>
  <id_info>
    <org_study_id>BA109</org_study_id>
    <nct_id>NCT04025710</nct_id>
  </id_info>
  <brief_title>Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)</brief_title>
  <official_title>BIO|MASTER.BIOMONITOR III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual&#xD;
      risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered&#xD;
      or remain even after risk analysis, risk mitigation and successful conformity assessment.&#xD;
      Furthermore, this study will also provide additional data as required by regulatory&#xD;
      authorities outside of the CE-region.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SADE-free rate until the 3-month follow-up</measure>
    <time_frame>3 months</time_frame>
    <description>SADE-free rate related to BIOMONITOR III and BIOMONITOR IIIm including incision and insertion tool set until 3-month follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R-wave amplitude</measure>
    <time_frame>10 days to 4 weeks after insertion; 3-months</time_frame>
    <description>The secondary endpoint 1 evaluates the R-wave amplitude at the 1st follow-up and at 3-month follow-up by measuring both, the lowest and the highest amplitude value via the programmer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noise burden</measure>
    <time_frame>10 days to 4 weeks after insertion; 3-months</time_frame>
    <description>The secondary endpoint 2 evaluates the noise burden at the 1st follow-up and at 3-month follow-up by retrieving the percentage of noise via the programmer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of P-wave visibility</measure>
    <time_frame>10 days to 4 weeks after insertion; 3-months</time_frame>
    <description>The secondary endpoint 3 evaluates the P-wave visibility at 1st, 3- and 12-month follow-up. The investigator will evaluate whether P-waves can be recognized in the stored sECGs showing sinus rhythm. The number of heart cycles and observed P-waves which can undoubtly be identified in ECGs will be assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SADE-free rate until the 12-month follow-up</measure>
    <time_frame>12-months</time_frame>
    <description>The secondary endpoint 4 is the SADE-free rate related to the BIOMONITOR III and BIOMONITOR IIIm 12 months after insertion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Tachyarrhythmia</condition>
  <condition>Atrial Fibrillation (AF)</condition>
  <condition>Syncope</condition>
  <condition>Cryptogenic Stroke</condition>
  <arm_group>
    <arm_group_label>all patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOMONITOR III and BIOMONITOR IIIm</intervention_name>
    <description>Insertion of BIOMONITOR III or BIOMONITOR IIIm&#xD;
three scheduled in-office follow-ups&#xD;
48-hour Holter ECG</description>
    <arm_group_label>all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is at high risk of developing a clinically important cardiac arrhythmia; or&#xD;
&#xD;
          -  Patient is undergoing investigation for symptoms such as palpitations, pre- syncope or&#xD;
             syncope, that are suggestive of an underlying cardiac arrhythmia; or&#xD;
&#xD;
          -  Patient is undergoing investigation for the detection of atrial fibrillation following&#xD;
             cryptogenic stroke; or&#xD;
&#xD;
          -  Patient is planned for AF ablative procedure or has already undergone an AF ablative&#xD;
             procedure.&#xD;
&#xD;
          -  Patient is able to understand the nature of the study and able to provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Patient is willing and able to perform all follow-up visits at the investigational&#xD;
             site.&#xD;
&#xD;
          -  Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home&#xD;
             Monitoring concept.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is implanted with an ICD or pacemaker.&#xD;
&#xD;
          -  Patient is pregnant or breast-feeding.&#xD;
&#xD;
          -  Patient is less than 18 years old.&#xD;
&#xD;
          -  Patient's life-expectancy is less than 12 months.&#xD;
&#xD;
          -  Patient is participating in another interventional clinical investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Deneke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RHÖN-KLINIKUM Campus Bad Neustadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GenesisCare Wesley</name>
      <address>
        <city>Auchenflower</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare Bundaberg</name>
      <address>
        <city>Bundaberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare Doncaster</name>
      <address>
        <city>Doncaster East</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canberra Heart Rhythm Clinic</name>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien (AKH)</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHÖN-KLINIKUM Campus Bad Neustadt</name>
      <address>
        <city>Bad Neustadt An Der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH (UKGM)</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt-Universität Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen Service GmbH</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Marien-Hospital GmbH</name>
      <address>
        <city>Lünen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Bierzo</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV - Centre Hospitalier Universitaire Vaudoise</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

